# GLP-1 Lean Mass Loss Against Control: 0.78 kg in a Three-Trial Meta-Analysis

A meta-analysis of three randomized trials in adults without type 2 diabetes | lean mass fell 0.78 kg more than control and fat mass 3.43 kg more, differences that sit beside larger absolute totals.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/glp1-lean-mass-compared-to-what
Updated: 2026-11-14
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Lean Mass Loss Against Control: 0.78 kg in a Three-Trial Meta-Analysis

Compared with control groups, lean mass fell 0.78 kg more and fat mass 3.43 kg more. Those are differences from a comparator, which is why larger absolute figures also hold.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20266 min readUpdated November 2026

Extra loss compared with control · fat mass · −3.43 kg · lean mass · −0.78 kg · Both are differences against a control group, not totals. · Lean mass includes nonmuscular tissue. · Three trials, 171 participants.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A meta-analysis of randomized trials in adults with obesity and without type 2 diabetes found three eligible trials covering 171 participants.
-   Against control, lean mass fell 0.78 kg more.
-   Against control, fat mass fell 3.43 kg more, 95% CI −5.94 to −0.93.
-   These estimates compare the change in treatment groups with the change in comparison groups.
-   Lean mass includes nonmuscular tissue, so the estimate cannot measure skeletal muscle loss alone.

In studies that measure [lean mass from baseline](https://buythisglp.com/research/does-a-glp1-cause-muscle-loss), the number describes the total change within a group. In the three-trial analysis below, 0.78 kg describes the difference in change between the treatment and comparison groups.

## What this analysis did

A search of five databases to the end of 2024 turned up 2,776 articles, of which three randomized trials covering 171 participants met the criteria: adults with obesity, without type 2 diabetes, on a GLP-1, with body composition reported. [\[1\]](https://buythisglp.com/research/glp1-lean-mass-compared-to-what#ref-1) On average, treatment groups lost 0.78 kg more lean mass and 3.43 kg more fat mass than comparison groups. The paper gives a slightly different lower confidence limit for lean mass in the abstract and results section. Heterogeneity was substantial for both outcomes, with I² of 63.2% for lean mass and 78.2% for fat mass.

Lean mass includes more than muscle

DXA lean mass includes nonmuscular tissue. The group difference measures a body-composition outcome across the included comparisons. It cannot tell you how many kilograms of skeletal muscle a person lost or separate the amount tied to weight loss from any other effects of treatment.

## What the split looks like

Taking the two point estimates at face value, the extra weight lost on the drug was about 18.5% lean and the rest fat. That division is our arithmetic rather than the paper’s — it uses only the central estimates, ignores both confidence intervals, and ignores the substantial heterogeneity. Treat it as a shape, not a measurement.

Our summary of [lean mass as a share of total weight lost](https://buythisglp.com/research/how-much-of-it-is-muscle) covers studies with different comparison groups and follow-up periods. The roughly one-third share discussed there cannot be compared directly with a ratio of two treatment-versus-control estimates.

## Why the evidence base is this small

Three trials met the eligibility criteria, which required randomization, body-composition measurements and participants without type 2 diabetes. With so few studies and substantial differences between estimates, the pooled numbers may change as more trials become available.

## What the findings can tell you

The authors discuss physical activity and nutrition alongside treatment. Our [review of lean mass and resistance exercise](https://buythisglp.com/research/does-a-glp1-cause-muscle-loss) covers a separate trial designed to test exercise during tirzepatide treatment. The three-trial meta-analysis did not establish a training plan or protein target.

## Frequently asked

Is the lean-mass loss 0.78 kg or six kilograms?

The 0.78 kg estimate compares changes between groups across three trials. Larger figures from other studies can describe the total change within a treatment group.

How much of the extra loss was fat?

Fat mass fell 3.43 kg more than control against 0.78 kg of lean. Dividing those point estimates gives roughly four-fifths fat, which is this site's arithmetic and ignores the confidence intervals.

Why only three trials?

The authors required randomized trials with body-composition measurements in adults without type 2 diabetes. Three trials met their criteria.

Does this change what to do about it?

The authors discuss adding physical activity and nutritional support. This analysis did not test a specific training plan or protein target.

## Sources

1.  \[1\] Woźniak M, et al. (2026). The Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis Journal of Clinical Medicine. [PMID 42739822](https://pubmed.ncbi.nlm.nih.gov/42739822/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
